<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02465437</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-SSc-001</org_study_id>
    <nct_id>NCT02465437</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis</brief_title>
  <official_title>A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of the study is an interventional, double-blind, randomized, placebo-control design
      will be used to test safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in
      subjects ≥ 18 and ≤ 70 years of age with active diffuse cutaneous systemic sclerosis. The
      screening period is up to 28 days, with 84 days treatment period and 28 days follow-up off
      active treatment.

      Part B of the study is an interventional, open-label design will be used. All subjects who
      complete dosing in Part A without permanent discontinuation of study drug and who pass repeat
      safety screening will be eligible for enrollment. The screening period is up to 28 days, with
      a 364 day treatment period and 28 day follow up after last dose of JBT-101.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events from baseline at Day 113</measure>
    <time_frame>Part A: 112 days, with 84 day treatment and 28 day follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) from baseline at Day 85</measure>
    <time_frame>Part A: 84 day treatment period</time_frame>
    <description>CRISS responders and its domains of modified Rodnan skin score, forced vital capacity percent predicted, Physician Global Assessment, Patient Global Assessment, and Health Assessment Questionnaire Disability-Index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events from baseline at Day 394</measure>
    <time_frame>Part B: 394 days, with 365 day treatment and 28 day follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Combined Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) from baseline at Day 394</measure>
    <time_frame>Part B: 365 day treatment period</time_frame>
    <description>CRISS responders and its domains of modified Rodnan skin score, forced vital capacity percent predicted, Physician Global Assessment, Patient Global Assessment, and Health Assessment Questionnaire Disability-Index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in patient-reported outcomes from baseline at Day 85</measure>
    <time_frame>84 day treatment period</time_frame>
    <description>National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS)-29 Short Form, the PROMIS-29 Short Form single item pain numerical rating score, the 5-D Itch Score, and a Systemic Sclerosis Skin Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in JBT-101 plasma concentrations from baseline at Day 85</measure>
    <time_frame>84 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolipidomic profile from baseline at Day 85</measure>
    <time_frame>84 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood biomarkers of disease activity, inflammation and fibrosis from baseline at Day 85</measure>
    <time_frame>84 day treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in skin biomarkers of inflammation and fibrosis from baseline at Day 85</measure>
    <time_frame>84 day treatment period</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Diffuse Cutaneous Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>JBT-101 5 mg/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 5 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg twice a day (bid) on Days 29-84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 20 mg/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 20 mg q am and placebo q pm on Days 1-28, then JBT-101 20 mg bid on Days 29-84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>JBT-101 20 mg bid/20 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 20 mg bid on Days 1-84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo bid on Days 1-84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B Open-label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JBT-101 20 mg bid on Days 1-364</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JBT-101</intervention_name>
    <description>JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.</description>
    <arm_group_label>JBT-101 5 mg/20 mg bid</arm_group_label>
    <arm_group_label>JBT-101 20 mg/20 mg bid</arm_group_label>
    <arm_group_label>JBT-101 20 mg bid/20 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.</description>
    <arm_group_label>JBT-101 5 mg/20 mg bid</arm_group_label>
    <arm_group_label>JBT-101 20 mg/20 mg bid</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Part B Open-Label Extension</intervention_name>
    <description>JBT-101 20mg bid on Days 1-364</description>
    <arm_group_label>Part B Open-label</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part A

          -  Diffuse cutaneous systemic sclerosis

          -  Have skin thickening from SSc in a body area suitable for repeat biopsy

          -  Disease duration ≤ 3 years from the first non-Raynaud's phenomenon or &gt;3 years and ≤ 6
             years from the first non-Raynaud's phenomenon and high sensitivity C-reactive protein
             &gt; 3 mg/L, high sensitivity interleukin-6 &gt; 5 pg/mL, or increase in mRSS ≥ 5 points
             over the last 6 months with total RSS ≥ 12.

          -  Stable treatment for SSc for at least 28 days before Visit 1

        Part B

        •Completion of dosing in Part A without permanent discontinuation of study product because
        of safety or tolerability reasons.

        Exclusion Criteria (Part A and B):

          -  Severe or unstable systemic sclerosis

          -  Significant diseases or conditions other than systemic sclerosis that may influence
             response to the study product or safety;

          -  Any one of the following values for laboratory tests at Screening:

               1. A positive pregnancy test (or at Visit 1);

               2. Hemoglobin &lt; 10 g/dL

               3. Neutrophils &lt; 1.0 x 10^9/L

               4. Platelets &lt; 75 x 10^9/L

               5. Creatinine clearance &lt; 50 ml/min according to modified Cockcroft-Gault equation

               6. Serum transaminases &gt; 2.0 x upper normal limit

               7. Total bilirubin ≥ 1.5 x upper limit of normal

          -  Any other condition that, in the opinion of the Principal Investigator, is clinically
             significant and may put the subject at greater safety risk, influence response to
             study product, or interfere with study assessments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Spiera, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical College, New York City, NY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arthritis Association of Southern CA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins Scleroderma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers University</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Houston Medical School</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 8, 2018</submitted>
    <returned>April 4, 2018</returned>
    <submitted>April 17, 2018</submitted>
    <returned>May 15, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

